OBJECTIVE: To investigate a potential effect of @entity10891 on serum neurofilaments (Nf) compared to placebo and the relationship between longitudinal clinical and MRI outcomes and serum Nf levels. METHODS: Serum samples were obtained from @entity1 enrolled in a randomized double-blind trial of neuroprotection with @entity10891 vs placebo as an add-on to weekly @entity2391 ( @entity2391 )-1a IM initiated 3 months after randomization. Nf measurements were performed by ELISA and electrochemiluminescence immunoassay. RESULTS: Longitudinal serum samples were available from 22 @entity10891 and 20 placebo @entity1 over 24 months. There was no observed treatment effect with @entity10891 . Nf light chain ( @entity20698 ) levels decreased over time (p = 0.007 at 24 months), whereas the Nf heavy chain was unchanged (p = 0.997). Changes in @entity20698 were correlated with EDSS change (p = 0.009) and neuropsychological outcomes. Brain volume decreased more rapidly in @entity1 with high baseline @entity20698 (p = 0.05 at 12 months and p = 0.008 at 24 months) and this relationship became stronger at 24 months (p = 0.024 for interaction). Higher and increasing @entity20698 predicted higher number of @entity2287 -enhancing lesions (p < 0.001 for both). CONCLUSIONS: Our findings support the potential value of serum @entity20698 as a marker of @entity130 in early @entity15 . Its reduction over time could represent regression to the mean, or a possible treatment effect of @entity2391 -1a. The association with whole @entity1010 and the formation of acute white matter lesions has relevant implications to use serum @entity20698 as a noninvasive biomarker of the overall consequences of @entity75 activity. CLINICALTRIALSGOV IDENTIFIER: NCT00501943.

Serum neurofilament is associated with progression of XXXX and disability in early @entity15 .

@entity1 :: ('9606', 'Species') :: ['participants', 'patients'] @entity20698 :: ('4747', 'Gene') :: ['NfL'] @entity75 :: ('MESH:D001927', 'Disease') :: ['brain damage and ongoing disease'] @entity10891 :: ('MESH:D019782', 'Chemical') :: ['riluzole'] @entity1010 :: ('MESH:C566985', 'Disease') :: ['brain atrophy'] @entity2391 :: ('3456', 'Gene') :: ['IFN-b', 'interferon-b'] @entity2287 :: ('MESH:D005682', 'Chemical') :: ['gadolinium'] @entity15 :: ('MESH:D009103', 'Disease') :: ['multiple sclerosis'] @entity130 :: ('MESH:D014947', 'Disease') :: ['neuroaxonal injury']
@entity1010 :: (MESH:C566985,Disease) :: ['brain atrophy']
